Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of “Moderate Buy” by Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $30.35.

Several equities analysts recently issued reports on NRIX shares. UBS Group started coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $41.00 target price on the stock. Finally, Royal Bank of Canada dropped their price target on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the sale, the insider now directly owns 50,670 shares of the company’s stock, valued at $1,231,281. The trade was a 6.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the completion of the transaction, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 9,351 shares of company stock worth $227,158. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NRIX. Renaissance Technologies LLC boosted its position in shares of Nurix Therapeutics by 80.7% during the second quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock worth $6,762,000 after purchasing an additional 144,700 shares in the last quarter. TD Asset Management Inc bought a new position in Nurix Therapeutics during the second quarter worth about $593,000. Barclays PLC grew its stake in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after acquiring an additional 56,190 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Nurix Therapeutics by 31.4% in the second quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company’s stock worth $4,365,000 after acquiring an additional 49,918 shares in the last quarter. Finally, FMR LLC raised its position in shares of Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after purchasing an additional 511,256 shares during the period.

Nurix Therapeutics Stock Down 1.8 %

Shares of NASDAQ:NRIX opened at $19.14 on Friday. Nurix Therapeutics has a twelve month low of $7.65 and a twelve month high of $29.56. The business has a 50 day moving average price of $21.14 and a 200 day moving average price of $22.45. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -6.58 and a beta of 2.14.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.